(Finance) – The title is moving downwards Modern which exhibits a negative percentage change of 4.95%.
The Massachusetts biotech said its flu vaccine under study didn’t meet all of its goals. In particular, efficacy has not been demonstrated for influenza B which is less frequent than A but which mainly affects a younger population.
The stock trend analyzed on a weekly basis shows a similar trend to that of NASDAQ 100. This means that the stock is supported by elements from the market rather than news related to the company itself.
The technical status of the American biotechnology company losing strength with prices leaning towards the supports estimated at USD 161. On the upside however, any appreciations would find a serious obstacle at 166.2. The confirmed dominance of the bears makes a continuation of the trend towards the 158.3 area concrete.